Biomedical accelerator mass spectrometry

Radiotracers in Drug Development

Volumn , Issue , 2006, Pages 233-249

  Lappin, Graham ^a  

^a UNIVERSITY OF WESTMINSTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84978896432     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (33)

1. Turteltaub, K.W., Felton, J.S., Gledhill, B.L., Vogel, J.S., Southon, J.R., Caffee, M.W., Finkel, R.C., Nelson, D.E., Proctor, I.D., and Davis, J.C., Accelerator mass spectrometry in biomedical dosimetry: relationship between low-level exposure and covalent binding of heterocyclic amine carcinogens to DNA, Proc. Natl. Acad. Sci. U.S.A., 87, 5288-5292, 1990.
2. Theodorsson, P., Measurement of Weak Radioactivity, World Scientific, Singapore, 1996.
3. Bennett, C.L., Beukens, R.P., Clover, M.R., Gove, H.E., Liebert, R.B., Litherland, A.E., Purser, K.H., and Sondheim, W.E., Radiocarbon dating with electrostatic accelerators:negative ions provide the key, Science, 198, 508-510, 1977.
4. Nelson, D.E., Korteling, R.G., and Stott, W.R., Carbon-14 direct detection at natural concentrations, Science, 198, 507-508, 1977.
5. Wilson, I., The Blood and the Shroud: The Passionate Controversy Still Enflaming the World’s Most Famous Carbon-Dating Test, Weidenfeld & Nicolson, London, 1998.
6. Kitagawa, H. and van der Plicht, J., Atmospheric radiocarbon calibration to 45,000 yr B.P.: late glacial fluctuations and cosmogenic isotope production, Science, 279, 1187-1190, 1998.
7. Moore, P.B., Day, J.P., Taylor, G.A., Ferrier, I.N., Fifield, L.K., and Edwardson, J.A., Absorption of aluminium-26 in Alzheimer’s disease, measured using accelerator mass spectrometry, Dement Geriatr. Cogn. Disord., 11, 66-69, 2000.
8. Barker, J. and Garner, R.C., Biomedical applications of accelerator mass spectrometry:isotope measurements at the level of the atom, Rapid Commun. Mass. Spectrom., 13, 285-293, 1999.
9. Schmidt, A., Schnabel, C., Handl, J., Jakob, D., Michel, R., Synal, H.A., Lopez, J.M., and Suter, M., On the analysis of iodine-129 and iodine-127 in environmental materials by accelerator mass spectrometry and ion chromatography, Sci. Total Environ., 223, 131-156, 1998.
10. Tuniz, C., Bird, J.R., Fink, D., and Herzog, G.F., Accelerator Mass Spectrometry, Ultrasensitive Analysis for Global Science, CRC Press, Boca Raton, FL, 1998.
11. Popplewell, J.F., King, S.J., Day, J.P., Ackrill, P., Fifield, L.K., Cresswell, R.G., di Tada, M.L., and Liu, K., Kinetics of uptake and elimination of silicic acid by a human subject: a novel application of 32Si and accelerator mass spectrometry, J. Inorg. Biochem., 69, 177-180, 1998.
12. Chiarappa-Zucca, M.L., Dingley, K.H., Roberts, M.L., Velsko, C.A., and Love, A.H., Sample preparation for quantitation of tritium by accelerator mass spectrometry, Anal. Chem., 74, 6285-6290, 2002.
13. Vogel, J.S., Production of carbon for accelerator mass spectrometry without contamination, Radioacarbon, 34, 344-350, 1992.
14. Ognibene, T.J., Bench, G., Vogel, J.S., Peaslee, G.F., and Murov, S., A high-throughput method for the conversion of CO2 obtained from biochemical samples to graphite in septa-sealed vials for quantification of 14C via accelerator mass spectrometry, Anal. Chem., 75, 2192-2196, 2003.
15. Turteltaub, K.W., Vogel, J.S., Frantz, C., Felton, J.S., and McManus, M., Assessment of the DNA adduction and pharmacokinetics of PhIP and MeIQx in rodents at doses approximating human exposure using the technique of accelerator mass spectrometry (AMS) and 32P-postlabeling, Princess Takamatsu Symp., 23, 93-102, 1995.
16. Mauthe, R.J., Dingley, K.H., Leveson, S.H., Freeman, S.P., Turesky, R.J., Garner, R.C., and Turteltaub, K.W., Comparison of DNA-adduct and tissue-available dose levels of MeIQx in human and rodent colon following administration of a very low dose, Int. J. Cancer, 80, 539-545, 1999.
17. Turteltaub, K.W., Mauthe, R.J., Dingley, K.H., Vogel, J.S., Frantz, C.E., Garner, R.C., and Shen, N., MeIQx-DNA adduct formation in rodent and human tissues at low doses, Mutat. Res., 376, 243-252, 1997.
18. Frantz, C.E., Bangerter, C., Fultz, E., Mayer, K.M., Vogel, J.S., and Turteltaub, K.W., Dose-response studies of MeIQx in rat liver and liver DNA at low doses, Carcinogenesis, 16, 367-373, 1995.
19. Lightfoot, T.J., Coxhead, J.M., Cupid, B.C., Nicholson, S., and Garner, R.C., Analysis of DNA adducts by accelerator mass spectrometry in human breast tissue after administration of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and benzo[a]pyrene, Mutat. Res., 472, 119-127, 2000.
20. Cupid, B.C., Lightfoot, T.J., Russell, D., Gant, S.J., Turner, P.C., Dingley, K.H., Curtis, K.D., Leveson, S.H., Turteltaub, K.W., and Garner, R.C., The formation of AFB(1)-macromolecular adducts in rats and humans at dietary levels of exposure, Food Chem. Toxicol., 42, 559-569, 2004.
21. Turteltaub, K.W., Dingley, K.H., Curtis, K.D., Malfatti, M.A., Turesky, R.J., Garner, R.C., Felton, J.S., and Lang, N.P., Macromolecular adduct formation and metabolism of heterocyclic amines in humans and rodents at low doses, Cancer Lett., 143, 149-55, 1999.
22. Young, G., Ellis, W., Ayrton, J., Hussey, E., and Adamkiewicz, B., Accelerator mass spectrometry (AMS): recent experience of its use in a clinical study and the potential future of the technique, Xenobiotica, 31, 619-632, 2001.
23. Liberman, R.G., Tannenbaum, S.R., Hughey, B.J., Shefer, R.E., Klinkowstein, R.E., Prakash, C., Harriman, S.P., and Skipper, P.L., An interface for direct analysis of (14)c in nonvolatile samples by accelerator mass spectrometry, Anal. Chem., 76, 328-334, 2004.
24. Lappin, G. and Garner, R.C., Current perspectives of 14C-isotope measurement in biomedical accelerator mass spectrometry, Anal. Bioanal. Chem., 378, 356-364, 2004.
25. White, I.N. and Brown, K., Techniques: the application of accelerator mass spectrometry to pharmacology and toxicology, Trends Pharmacol. Sci., 25, 442-447, 2004.
26. Garner, R.C., Goris, I., Laenen, A.A., Vanhoutte, E., Meuldermans, W., Gregory, S., Garner, J.V., Leong, D., Whattam, M., Calam, A., and Snel, C.A., Evaluation of accelerator mass spectrometry in a human mass balance and pharmacokinetic studyexperience with 14C-labeled (R)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone (R115777), a farnesyl transferase inhibitor, Drug Metab. Dispos., 30, 823-830, 2002.
27. Kaye, B., Garner, R.C., Mauthe, R.J., Freeman, S.P., and Turteltaub, K.W., A preliminary evaluation of accelerator mass spectrometry in the biomedical field, J. Pharm. Biomed. Anal., 16, 541-543, 1997.
28. Leide-Svegborn, S., Stenstrom, K., Olofsson, M., Mattsson, S., Nilsson, L.-E., Nosslin, B., Pau, K., Johansson, L., Erlandsson, B., Hellborg, R., and Skog, G., Biokinetics and radiation doses for carbon-14 urea in adults and children undergoing the Helicobacter pylori breath test, Eur. J. Nuclear Med., 26, 573-580, 1999.
29. Garner, R.C., Garner, J.V., Gregory, S., Whattam, M., Calam, A., and Leong, D., Comparison of the absorption of micronized (Daflon 500 mg) and nonmicronized 14C-diosmin tablets after oral administration to healthy volunteers by accelerator mass spectrometry and liquid scintillation counting, J. Pharm. Sci., 91, 32-40, 2002.
30. Strong, J.M., Dutcher, J.S., Lee, W.K., and Atkinson, A.J., Jr., Absolute bioavailability in man of N-acetylprocainamide determined by a novel stable isotope method, Clin. Pharmacol. Ther., 18, 613-622, 1975.
31. Wilding, I.R., Davis, S.S., Hardy, J.G., Robertson, C.S., John, V.A., Powell, M.L., Leal, M., Lloyd, P., and Walker, S.M., Relationship between systemic drug absorption and gastrointestinal transit after the simultaneous oral administration of carbamazepine as a controlled-release system and as a suspension of 15N-labelled drug to healthy volunteers, Br. J. Clin. Pharmacol., 32, 573-579, 1991.
32. European Medicines Evaluation Agency (EMEA), Position Paper on Non-clinical Safety Studies to Support Clinical Trials with a Single Microdose, position paper CPMP/SWP/2599, June 23, 2004.
33. Lappin, G. and Garner, R.C., Big physics, small doses: the use of AMS and PET in human microdosing of development drugs, Nat. Rev. Drug Discov., 2, 233-240, 2003.